Celsion Corp
Change company Symbol lookup
Select an option...
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
LTTTX MFS Lifetime 2025 Fund Class R3
HLI Houlihan Lokey Inc
KICK Master Glazier's Karate International Inc
VIRT Virtu Financial Inc
FB Facebook Inc
ED Consolidated Edison Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Value
Company profile

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Closing Price
Day's Change
-0.03 (-3.33%)
B/A Size
Day's High
Day's Low

10-day average volume:

Visa, Mastercard, American Express stocks surge on hopes for travel recovery amid upbeat vaccine news

1:55 pm ET November 9, 2020 (MarketWatch)

By Emily Bary

Shares of PayPal, which has benefitted from surging e-commerce usage, are falling

Pfizer Inc. and BioNTech SE's upbeat vaccine news is giving a lift to many payments stocks Monday amid hope that a vaccine can revive the global travel landscape and drive a broader recovery in consumer spending.

Shares of Visa Inc. (V) are up 9% in Monday trading, while shares of Mastercard Inc. (MA) are up more than 11% after Pfizer (PFE) and BioNTech (BNTX) said that their vaccine candidate had shown 90% effectiveness in preventing COVID-19, a much higher threshold than originally expected (https://www.marketwatch.com/story/biontech-and-pfizer-say-their-covid-19-vaccine-candidate-is-90-effective-2020-11-09?mod=home-page).

"With a vaccine showing good progress, we think the travel-sensitive and [small- and medium-sized business]-sensitive stocks could rally," Baird analyst David Koning wrote in a note to clients. Visa and Mastercard generate about 20% to 25% of their revenue from cross-border travel, he wrote, and this category may have been down by 70% to 75% in recent months by his estimation.

Mastercard noted on its last conference call that global travel has largely been stalled (https://www.marketwatch.com/story/mastercard-stock-falls-after-weak-travel-spending-pressures-earnings-11603887433), with the exception of some travel between countries within the European Union. Those intra-Europe transactions are "lower yielding" than other cross-border transactions, Chief Financial Officer Sachin Mehra said. That means that Mastercard keeps a bigger portion of the transaction when processing cross-border payments between customers and merchants who aren't both from the EU.

In addition, credit spending has been depressed while consumers have shown a preference for debit cards (https://www.marketwatch.com/story/visa-says-covid-19-crisis-could-help-drive-100-billion-annual-shift-to-debit-cards-over-time-2020-06-03), viewed as a more conservative payment instrument. "Travel, by and large, happens to be more credit-oriented," Mehra said on Mastercard's earnings call in late October, so the company expects to see a rebound in that part of the business once international travel rebounds.

Read: Visa and Mastercard have a lot in common, but COVID-19 puts one key difference in focus (https://www.marketwatch.com/story/visa-and-mastercard-have-a-lot-in-common-but-covid-19-puts-one-key-difference-in-focus-11604090026)

Shares of American Express Co. (AXP) are leading the Dow Jones Industrial Average higher Monday, up 21% in the session. Travel and entertainment are the company's "bread and butter," according to Susquehanna analyst James Friedman, who wrote that these areas made up 26% to 30% of the company's booked business in the quarters leading up to the pandemic, "with airlines alone at 7% to 9%."

American Express also provides corporate travel services. In general, business travel has been slow to bounce back even as domestic personal travel picks up. "If you look at our corporate card business, obviously, there's...hardly anybody that is sort of traveling at this point," Chief Executive Stephen Squeri said on the American Express earnings call in October.

The hope is that a vaccine could help bring more normalcy to the way people work.

See more: Financial stocks soar, led by American Express after upbeat news on potential COVID-19 vaccine (https://www.marketwatch.com/story/financial-stocks-soar-led-by-american-express-after-upbeat-news-on-potential-covid-19-vaccine-2020-11-09)

While the big credit-card names are up sharply in Monday's session, new-school payments names whose stocks have rallied since the start of the pandemic are falling. These include PayPal Holdings Inc. (PYPL), which has seen record spending (https://www.marketwatch.com/story/paypal-earnings-bolstered-by-pandemics-e-commerce-boom-11604352643) on its platform as the COVID-19 crisis has driven more people to buy things online and brought more consumers, especially older generations, into the digital fray.

PayPal shares are down about 6% in the session.

In a sign of how much Square Inc.'s (SQ) narrative has shifted since the start of the pandemic, its stock is also trading lower Monday, off about 5%.

Square is known for providing payment-processing services to small businesses, and its stock fell in the early days of the crisis (https://www.marketwatch.com/story/heres-why-square-could-be-seen-as-a-proxy-for-the-most-vulnerable-businesses-2020-03-18) amid fears that local merchants would be especially pressured by restrictions on business activity. A vaccine should help those small businesses, but Square's stock appears to be taking a breather after what turned out to be a 150% rally over the past six months, once investors came to see more value in other parts of the company's business such as the Cash App mobile wallet (https://www.marketwatch.com/story/venmo-and-square-cash-were-going-gangbusters-before-the-pandemicnow-theyre-doing-even-better-2020-06-18) and online stores for merchants.

Other names that could benefit from a bounce back for small businesses include processors Fiserv Inc. (FISV), Fidelity National Information Services Inc. (FIS), and Global Payments Inc. (GPN), according to Baird's Koning. He calculates that about 10% to 15% of revenue for Fiserv and FIS is driven by brick-and-mortar small- and medium-sized businesses, along with perhaps 25% to 30% of revenue for Global Payments. All three should see "very easy" comparisons in the second quarter of 2021, he wrote.

Fiserv shares are up 8.6% in midday trading Monday, while FIS shares are up 8.5% and Global Payments shares are up 12.7%.

-Emily Bary; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 09, 2020 13:55 ET (18:55 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.